Please wait while the formulary information is being retrieved.
TRI-LUMA (FLUOCINOLONE ACETONIDE/TRETINOIN/HYDROQUINONE)
- Chloasma
0.01 %-4 %-0.05 % topical cream
- Apply to the affected area(s) by topical route once daily at night 30Minutes before bedtime
Chloasma
- Apply to the affected area(s) by topical route once daily at night 30Minutes before bedtime
- None
Contraindicated
- Adoxa
- Avidoxy
- demeclocycline
- Doryx
- Doxy-100
- doxycycline calcium
- doxycycline hyclate
- doxycycline monohydrate
- First-mary's Mouthwash
- Minocin
- minocycline
- Monodox
- Morgidox
- nystatin-TCN-HC-diphenhydramin
- Oracea
- Solodyn
- tetracycline
- Vibramycin
Severe
Moderate
- None
- None
Contraindicated
- Eczema
- Sunburn
Severe
Moderate
- Hypothalamic-pituitary insufficiency
TRI-LUMA (FLUOCINOLONE ACETONIDE/TRETINOIN/HYDROQUINONE)
- Chloasma
- None
- Abnormal desquamation
- Erythema
- Skin photosensitivity
- Stinging of skin
More Frequent
Severe
Less Severe
- Contact dermatitis
- Folliculitis
- Hypersensitivity drug reaction
- Purpura
- Skin and skin structure infection
- Skin atrophy
- Headache disorder
- Paresthesia
- Pruritus of skin
- Skin rash
- Telangiectasia
- Treatment site sequelae
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Adrenal cortical insufficiency
- Blistering skin
- Bullous dermatitis
- Cataracts
- Central serous chorioretinopathy
- Dyschromia
- Glaucoma
- Hypothalamic-pituitary insufficiency
- Ocular hypertension
- Skin crusting
- Skin hypopigmentation
- Skin inflammation
- Skin striae
- Skin ulcer
- Urticaria
Less Severe
- Acneiform eruption
- Alopecia
- Blistering skin
- Contact dermatitis
- Dry skin
- Dyschromia
- Edema
- Glycosuria
- Hirsutism
- Hypercortisolism
- Hyperesthesia
- Hyperglycemia
- Miliaria
- Perioral dermatitis
- Skin irritation
Contraindicated
None
Severe Precaution
Fluocinolone Acetonide
Risk of HPA-Axis suppression. Growth inhibition with chronic use.
- 1 Day – 18 Years
- Risk of HPA-Axis suppression. Growth inhibition with chronic use.
Management or Monitoring Precaution
Hydroquinone (Topical)
Safety and efficacy not established age < 12 years.
- 1 Day – 12 Years
- Safety and efficacy not established age < 12 years.
Tretinoin (Top)
Safety and efficacy not established age < 12 years.
- 1 Day – 12 Years
- Safety and efficacy not established age < 12 years.
Fluocinolone Acetonide
- Severity Level:
C
- Additional Notes: Systemic absorp unknown;poss risk of orofacial clefts w/systemic corticosteroids
Hydroquinone
- Severity Level:
C
- Additional Notes:
Tretinoin (topical)
- Severity Level:
2
- Additional Notes: Fda cat c; formal consensus lacking regarding safe use of top tretinoin in preg
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Fluocinolone Acetonide
Amount of systemic absorption unknown, caution advised.
Insufficient data available
Caution should be exercised.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Amount of systemic absorption unknown, caution advised. |
Hydroquinone
Amount of systemic absorption unknown, caution advised.
Insufficient data available
Caution should be exercised.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
Tretinoin (retinoic Or Vit A Acid-top)
Amount of systemic absorption unknown, caution advised.
Insufficient data available
Caution should be exercised.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Caution should be exercised. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Fluocinolone Acetonide(topical)
Skin-Pre-existing skin atrophy increases risk of purpura and skin lacerations.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Chloasma | |
| H02.71 | Chloasma of eyelid and periocular area |
| H02.711 | Chloasma of right upper eyelid and periocular area |
| H02.712 | Chloasma of right lower eyelid and periocular area |
| H02.713 | Chloasma of right eye, unspecified eyelid and periocular area |
| H02.714 | Chloasma of left upper eyelid and periocular area |
| H02.715 | Chloasma of left lower eyelid and periocular area |
| H02.716 | Chloasma of left eye, unspecified eyelid and periocular area |
| H02.719 | Chloasma of unspecified eye, unspecified eyelid and periocular area |
| L81.1 | Chloasma |
| 0-9 | A-Z |
|---|---|
| H02.71 | Chloasma of eyelid and periocular area |
| H02.711 | Chloasma of right upper eyelid and periocular area |
| H02.712 | Chloasma of right lower eyelid and periocular area |
| H02.713 | Chloasma of right eye, unspecified eyelid and periocular area |
| H02.714 | Chloasma of left upper eyelid and periocular area |
| H02.715 | Chloasma of left lower eyelid and periocular area |
| H02.716 | Chloasma of left eye, unspecified eyelid and periocular area |
| H02.719 | Chloasma of unspecified eye, unspecified eyelid and periocular area |
| L81.1 | Chloasma |
Formulary Reference Tool